A country guide to clinical trials in Türkiye; regulatory timelines, hospital networks, patient access, therapeutic strengths, and an underutilized research market bridging Europe, Asia, and the Middle East.
Türkiye straddles two continents; the vast majority of its territory lies in Anatolia (Western Asia) while a small western portion sits in the Balkans (Southeast Europe). This unique geography makes it a bridge between East and West, sharing borders with Greece and Bulgaria to the northwest; Georgia, Armenia, and Iran to the east; and Iraq and Syria to the south. With a land area of 783,562 km² and a population of over 85 million, Türkiye is one of the most populous countries in both Europe and the Middle East.
Istanbul; Europe's largest city by population at over 15 million; dominates the country's economic, cultural, and medical landscape, alongside the capital Ankara (3.5M) and the Aegean city of İzmir. The country's pharmaceutical market reached approximately $6.7 billion in 2020, and its healthcare system, anchored by a universal General Health Insurance (GHI) scheme, covers virtually the entire population through a network of over 1,500 public, private, and university-affiliated hospitals.
Türkiye's 85 million people are predominantly ethnically Turkish, with Kurdish, Arab, and smaller minority populations adding demographic diversity. A relatively young median age (~33 years) and a high literacy rate (over 95%) make the country well-suited for a broad range of trial designs. Urban migration has concentrated large patient populations in Istanbul, Ankara, and İzmir, where the country's largest and best-equipped research hospitals are located.
Crucially, Türkiye has a low per-capita ratio of clinical trials; which means patients who are eligible are far less likely to be enrolled in competing studies than in Western Europe. This translates directly into large pools of treatment-naïve patients across oncology, cardiology, and neurology. The volume of clinical trials has been doubling approximately every three years, signaling rapid market maturation with significant headroom for further growth.
Untapped potential: Türkiye has over 85 million people but a clinical trial per capita rate significantly below Western Europe; making it one of the most under-researched large populations in the world relative to its healthcare infrastructure. For sponsors seeking naïve patients at scale, few countries present a comparable opportunity.
Türkiye's appeal in clinical research rests on a combination of population scale, cost efficiency, and a rapidly improving regulatory environment. The Turkish Medicines and Medical Devices Agency (TITCK) and the parallel Ethics Committee (EC) now grant approvals in as little as 4–6 weeks when no additional questions are raised; making Türkiye one of the fastest-approval markets globally. No IMPD is required for submission (a significant simplification vs. EU requirements), and most documents can be submitted in English.
TITCK and Ethics Committee approvals run in parallel. Approval can be obtained in 4–6 weeks when no questions are raised. No IMPD required. No import/export license needed for study drugs in many cases.
Significantly lower operational costs than Western Europe or the US. Competitive investigator fees, lower overhead, and a cost-effective logistics environment; without sacrificing data quality or GCP compliance.
85 million people with a low per-capita trial density means large treatment-naïve patient pools across all major therapeutic areas. High patient motivation; universal GHI coverage ensures accessible, organized referral pathways.
1,500+ hospitals; 100+ production plants; 33 R&D facilities. Over 171,000 physicians. Major cities feature modern City Hospitals (şehir hastaneleri) built to international standards. Top-10 global medical tourism destination.
Oncology is Türkiye's dominant and fastest-growing therapeutic area for clinical trials, driven by increasing cancer incidence and the country's investment in specialist oncology hospitals and university cancer institutes. Cardiology and neurology round out the top three. Türkiye has also developed a particular strength in rare disease research, supported by its population genetics; including founder populations in Anatolia with high frequencies of specific inherited conditions that make the country uniquely valuable for rare disease natural history studies and gene therapy trials.
Türkiye's leading research sites are concentrated in Istanbul, Ankara, and İzmir. University hospitals affiliated with Hacettepe, Istanbul, Ankara, Ege, Marmara, and Gazi universities form the backbone of the country's clinical research infrastructure, supplemented by modern city hospitals and private specialist centers.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Hacettepe University Hospitals | Ankara | Turkey's #1-ranked medical university (US News); 1,400+ beds; JCI-accredited (first public hospital in Turkey); 65+ active international clinical trials; strong oncology, hematology, and pediatrics focus; FDA and EMA inspection track record. |
| 02 | Istanbul University; Istanbul Medical Faculty Hospital (Çapa) | Istanbul | Turkey's oldest medical school (est. 1827); large academic hospital at the Çapa campus; broad multi-specialty trial portfolio; M8 Partnership with 25 international medical schools. |
| 03 | Ankara Bilkent City Hospital | Ankara | Modern purpose-built city hospital; dedicated Clinical Research Center; Phase I unit with PIC/S member TITCK accreditation; first-in-human capability; 24-hour volunteer database; advanced monitoring infrastructure. |
| 04 | Ankara University Medical Faculty Hospital | Ankara | Turkey's first medical school (est. 1946); Ibni Sina Hospital campus; strong research culture; oncology, cardiology, and neurology trial activity. |
| 05 | Istanbul University-Cerrahpaşa Medical Faculty Hospital | Istanbul | Major Istanbul academic hospital; 7th in Turkey for surgery international collaboration (US News); broad Phase II–IV trial portfolio; oncology and cardiovascular focus. |
| 06 | Ege University Medical Faculty Hospital | İzmir | Western Turkey's primary academic research hospital; 11th globally for clinical medicine international collaboration; oncology, hematology, and infectious disease specialist. |
| 07 | Marmara University Training Hospital | Istanbul | International-standard facilities; oncology, cardiology, and internal medicine trials; English-taught programs facilitate international investigator collaboration. |
| 08 | Gazi University Medical Faculty Hospital | Ankara | Established 1979; major Ankara research hospital; 929 academicians; oncology, cardiology, neurology, and hematology trials. |
| 09 | Dokuz Eylül University Hospital | İzmir | Aegean region academic research hub; oncology, cardiology, and rare disease trials; international collaboration network. |
| 10 | Koç University Hospital | Istanbul | Private academic hospital; JCI-accredited; international-standard facilities; increasingly active in commercial Phase II–IV trials; bilingual research staff. |
| 11 | Acıbadem University Hospital | Istanbul | Major private hospital network; JCI-accredited; oncology, cardiology, and neurology focus; strong international patient and sponsor relationships. |
| 12 | University of Health Sciences Türkiye; Research Hospitals | Istanbul / National | Network of Ministry of Health training and research hospitals; first university to meet 70 international medical education criteria; English-language programs; national trial footprint. |
| 13 | Karadeniz Technical University Medical Faculty | Trabzon | Black Sea region academic research hub; oncology and hematology focus; access to Black Sea coastal patient populations not typically covered in Istanbul/Ankara-centric studies. |
| 14 | Çukurova University Medical Faculty Hospital | Adana | Southern Turkey's primary academic research center; oncology, cardiology, and infectious disease; access to distinct Mediterranean and Middle Eastern heritage patient populations. |
| 15 | Mersin University Medical Faculty Hospital | Mersin | Regional research center; growing Phase II–IV portfolio; oncology, nephrology, and cardiovascular trials; port city with logistical advantages for IMP distribution. |
Turkey's #1-ranked medical university (US News); 1,400+ beds; JCI-accredited (first public hospital in Turkey); 65+ active international clinical trials; strong oncology, hematology, and pediatrics focus; FDA and EMA inspection track record.
Turkey's oldest medical school (est. 1827); large academic hospital at the Çapa campus; broad multi-specialty trial portfolio; M8 Partnership with 25 international medical schools.
Modern purpose-built city hospital; dedicated Clinical Research Center; Phase I unit with PIC/S member TITCK accreditation; first-in-human capability; 24-hour volunteer database; advanced monitoring infrastructure.
Turkey's first medical school (est. 1946); Ibni Sina Hospital campus; strong research culture; oncology, cardiology, and neurology trial activity.
Major Istanbul academic hospital; 7th in Turkey for surgery international collaboration (US News); broad Phase II–IV trial portfolio; oncology and cardiovascular focus.
Western Turkey's primary academic research hospital; 11th globally for clinical medicine international collaboration; oncology, hematology, and infectious disease specialist.
International-standard facilities; oncology, cardiology, and internal medicine trials; English-taught programs facilitate international investigator collaboration.
Established 1979; major Ankara research hospital; 929 academicians; oncology, cardiology, neurology, and hematology trials.
Aegean region academic research hub; oncology, cardiology, and rare disease trials; international collaboration network.
Private academic hospital; JCI-accredited; international-standard facilities; increasingly active in commercial Phase II–IV trials; bilingual research staff.
Major private hospital network; JCI-accredited; oncology, cardiology, and neurology focus; strong international patient and sponsor relationships.
Network of Ministry of Health training and research hospitals; first university to meet 70 international medical education criteria; English-language programs; national trial footprint.
Black Sea region academic research hub; oncology and hematology focus; access to Black Sea coastal patient populations not typically covered in Istanbul/Ankara-centric studies.
Southern Turkey's primary academic research center; oncology, cardiology, and infectious disease; access to distinct Mediterranean and Middle Eastern heritage patient populations.
Regional research center; growing Phase II–IV portfolio; oncology, nephrology, and cardiovascular trials; port city with logistical advantages for IMP distribution.
Türkiye's research ecosystem is built around a modernizing regulator (TITCK), top-tier academic university hospitals, and a growing network of specialist CROs experienced in bridging Turkish operations to global sponsors.
National competent authority for clinical trial authorization; parallel EC review; 4–6 week approval when no queries raised; no IMPD required; aligned with ICH and EMA standards.
Oversees the universal General Health Insurance system and the national hospital network; driving regulatory modernization and a city hospital program building research capacity nationwide.
Manages the General Health Insurance scheme covering virtually all residents; healthcare financing and hospital contracting body enabling structured patient access for clinical trial recruitment.
Turkey's top-ranked medical institution; 65+ active international trials; Hacettepe Institute of Oncology; JCI-accredited; first Turkish public institution to achieve JCI standards.
Dedicated translational research center affiliated with Koç University Hospital; bridges laboratory discovery and clinical trial implementation; international collaboration focus.
Experienced Türkiye-based team; 95% enrollment target achievement rate; full regulatory and contracting management; multiple therapeutic areas including oncology and rare diseases.
Dedicated Turkish CRO; partnerships with leading SMOs; Phase I–IV and observational study capability; strong audit support track record.
Istanbul-headquartered consultancy and CRO; ISO 9001, 27001, and 27701 certified; Phase I–IV and PMOS; Europe, US, MENA, and Africa service footprint.
Regulatory and clinical research consultancy; deep TITCK expertise; EU-Türkiye regulatory bridge for non-EU sponsors requiring local representation.
Türkiye is a clinical research market in accelerated transition. Its 85 million people, low per-capita trial exposure, fast 4–6 week regulatory approvals, and competitive costs make it structurally attractive for any sponsor seeking treatment-naïve patients at scale. The trial volume has been doubling every three years. Major regulatory reforms; including the simplification of TITCK's approval process and the construction of new city hospitals across the country; are removing historic barriers. For sponsors willing to act before the market becomes fully saturated, Türkiye offers one of the most compelling risk-reward profiles in global clinical research today.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.